This Week in BMC Cancer

Premium

Università di Pisa's Fotios Loupakis and colleagues report in BMC Cancer on their retrospective analysis of whether certain VEGF polymorphisms affect the efficacy of first-line FOLFIRI plus bevacizumab in treating metastatic colon cancer. The researchers analyzed the genomic DNA of 111 patients receiving that treatment and determined their VEGF polymorphisms using PCR-RFLP.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.